OTC Watch

All stocks / GNVR

Genvor Inc GNVR

Genvor (GNVR): shares outstanding up 23% in a year, convertible notes mentioned in an 8-K in June 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

DilutionEstimated floatCostly financing OTCQBNevada, USA
Live quote on OTC Markets

Market listing

Full name
GENVOR INC
Market tier
OTCQB
Trading status
Active
Last trade
Nov 11
Website
genvor.com
Source: Stockwatch, 2026-11-17

News headlines

Genvor's Antimicrobial Peptides Advance into Sugar Beet Research
2026-07-27 08:00 · News Release
Genvor Appoints Donald Kalkofen as Chief Financial Officer
2026-05-21 08:00 · News Release
Genvor Announces Strategic Memorandum of Understanding with Canlab International(TM) to Advance Commercial Peptide Pipeline
2026-04-14 08:00 · News Release
Genvor to Present at Centri Capital Conference on April 14
2026-04-07 08:01 · News Release
Genvor, Inc. Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026
2026-03-05 08:00 · News Release
Genvor Announces Strategic Expansion into Health and Wellness Market, Leveraging Proprietary AI-Accelerated BioCypher Platform to Develop Consumer Peptide Solutions
2026-03-04 08:00 · News Release
Genvor's AGM182 Antifungal Peptide Technology Validated in Peer-Reviewed Publication in PhytoFrontiers(TM)
2026-02-11 08:00 · News Release
Genvor Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization
2026-01-28 08:05 · News Release
Genvor, Inc. to Present at the 3rd Annual DealFlow Discovery Conference
2026-01-20 07:00 · News Release
Genvor to Present at the Life Sciences Virtual Investor Forum December 11th
2025-12-04 08:00 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-09-30
The report says
Net loss
($5,589,041)
What it means

It spends more than it earns

Under strain

The company lost $5.6 million in the year. It reported no sales.

The report says
Cash and cash equivalents
$37,231
Net cash used in operating activities
($555,717)
What it means

The cash could run out soon

Under strain

It had $37,231 in the bank and used about $46,310 a month. At that pace the money lasts less than a month unless it borrows or sells more shares.

The report says
Total assets
$45,822
Total liabilities
$1,358,204
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $45,822. Its debts and unpaid bills add up to $1.4 million. That is about $29.64 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Dilution2026-08-14

Shares outstanding rose from 29,634,608 (2025-07-31) to 36,410,120 (2026-08-14), up 23%.

Rule: Shares outstanding up 20% or more in 12 months. Source record

Estimated float2026-08-14

Estimated float about 28,286,120 shares as of 2026-08-14: 36,410,120 outstanding minus 8,124,000 held by 3 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Costly financing2026-06-22

8-K filed 2026-06-22 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Costly financing2026-04-22

8-K filed 2026-04-22 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Shares outstanding

Source: SEC filings
2025-09-30
30.2M
2025-12-08
34.5M
2025-12-31
34.4M
2026-02-11
34.4M
2026-03-31
36.0M
2026-05-13
36.2M
2026-06-30
36.4M
2026-08-14
36.4M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-03 4
2026-10-26 8-KCURRENT REPORT
2026-10-19 8-KCURRENT REPORT
2026-08-14 10-QQUARTERLY REPORT
2026-07-31 DEF 14CDEFINITIVE INFORMATION STATEMENT
2026-07-20 PRE 14CPRELIMINARY INFORMATION STATEMENT
2026-06-22 8-KCURRENT REPORT
2026-05-26 3
2026-05-21 8-K
2026-05-13 10-Q
2026-05-11 8-K
2026-04-22 8-K

Common questions about GNVR

Does GNVR file reports with the SEC?

Yes. Genvor files with the SEC under company number 0001792941. The most recent filing we hold is a 4 dated 2026-11-03.

Source record

How many GNVR shares are outstanding?

36,410,120 shares as of 2026-08-14, as reported to the SEC. That is up 23% from 29,634,608 on 2025-07-31.

Source record

Has GNVR filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs Genvor?

Officers named in its insider filings: Jessee M Jaynes (Chief Research Officer), Donald A. Kalkofen (Chief Financial Officer) and Chad Lee Pawlak Sr. (Chief Executive Officer).

Source record

Is Genvor making money?

The company lost $5.6 million in the year. It reported no sales. (Annual figures to 2025-09-30. Facts from the company's own report, not a recommendation.)

Source record